ADC Therapeutics to Report Second Quarter 2020 Financial Results on August 18, 2020Business Wire • 08/12/20
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With IbrutinibBusiness Wire • 07/17/20
ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab TesirineBusiness Wire • 07/06/20